November 17, 2016 / 9:46 PM / 3 years ago

BRIEF-Biospecifics Technologies announces positive data from mid-stage study in patients with cellulite

Nov 17 (Reuters) - Biospecifics Technologies Corp -

* CCH was well-tolerated in actively treated subjects with most adverse events being mild to moderate in severity

* Trial subjects receiving CCH showed statistically significant levels of improvement in appearance of cellulite with treatment

* Press release - Biospecifics Technologies Corp announces positive data from phase 2b study of CCH in patients with cellulite Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below